*2.1.1 Maintenance therapy in the recurrent setting*

Lynparza® (olaparib) is a first-in-class, small molecule, PARPi approved initially as monotherapy for maintenance treatment of patients in response to their most recent platinum-based regimen in olaparib (capsule formulation) in platinumsensitive, relapsed, BRCA-mutated HGSOC in the EU based on the results of Study 19. [21] In 2014, there were no agents for maintenance treatment of EOC after a response to platinum-containing regimens, and standard of care (SOC) was not clearly established in this setting.


**Table 1.**

*Current PARPi approved indications in ovarian cancer.*
